IFW

Docket No. 13323-105002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Lene Moller

Serial No.:

10/587,767

Group Art Unit:

1656

Filed:

October 17, 2006

Examiner:

Marsha M. Tsay

Confirmation

9900

For:

Haemostatic Sprays and Compositions

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching. 1. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed: 2. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application. 3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed ___. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement 4. M since it is being filed in compliance with: 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the

national stage as set forth in §1.491 in an international application; or

	\boxtimes	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
		37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5.	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.	
6.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):	
		A check in the amount of \$180.00 is enclosed in payment of the fee.
		Charge the fee to Deposit Account No. <u>50-3732</u> , Order No
7.	A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:	
		ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and
		the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 elow.
8.	This I	nformation Disclosure Statement is being filed in compliance with:
	a. [37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
	b. 🗌	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
	c. 🗌	The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9.	I hereby certify that each item of information contained in this Information Disclosure	

	counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.				
	I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
10.	This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application.				
11.	A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).				
	Charge any fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No				
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13323-105002.				
	Respectfully submitted, KING & SPALDING LLP				
Dated: Fo	Jonathan D. Ball Reg. No. 59,928				
Correspondence Address:					
King & Spalding LLP					
1185 Avenue of the Americas					
New York, NY 10036					
212-556-2100 Telephone 212-556-2222 Facsimile					
Z1Z-JJU-	212-330-2222 1 acsimile				

Certificate of Express Mailing Under 37 CFR 1.10

Thereby certify that the correspondence listed below is being deposited with sufficient postage with the United States Postal Service as "Express Mail Post Office to Addressee" under 37 CFR 1.10 on the date indicated below and addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Serial No.:

10/587,767

Express Mail Label No.:

EV 301013511 US

Docket No.:

13323-105002

Deposit Date:

February 15, 2008

Papers Submitted: Information Disclosure Statement, including forms PTO/SB/08a and PTO/SB/08b (16 pages); CD-Rom containing references cited; Certificate of Express Mailing; and Return Receipt Postcard herewith

Kathryn/M/Manginell